Brief: Adicet Bio Q3 Basic EPS USD -0.29
Brief: Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adicet Bio Reports Inducement Grant Under Nasdaq Listing Rule
Brief: Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Adicet Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Adicet Bio Inc expected to post a loss of 32 cents a share - Earnings Preview
Brief: Adicet Bio Q2 Basic EPS USD -0.34
Brief: Adicet Bio Q1 Basic EPS USD -0.31
Brief: Adicet Bio Announces Oral Presentation Highlighting Preclinical Adi-270 Data At The American Society Of Gene And Cell Therapy 28Th Annual Meeting
Brief: Adicet Bio Appoints Michael Grissinger To The Board Of Directors
Brief: Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adicet Bio Inc Files For Mixed Shelf Of Up To $250 Million
Brief: Adicet Bio Q4 Basic EPS USD -0.32
Brief: Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement
Brief: Adicet Bio Provides Corporate Update
Brief: Adicet Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adicet Bio Appoints Julie Maltzman, M.D. As Chief Medical Officer
Brief: Adicet Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Adicet Bio Inc reports results for the quarter ended in September 30 - Earnings Summary